Targeting the JAK2-STAT5 pathway in CML.

In this issue of Blood, Gallipoli et al show that combined targeting of BCR/ABL1 and Janus kinase 2 (JAK2) by 2 established kinase inhibitors, nilotinib (NI) and the JAK1/2 kinase inhibitor ruxolitinib (RUX), results in synergistic growth inhibition in immature CD34+ stem and progenitor cells obtained from patients with chronic myeloid leukemia (CML).